Device Trial Radar · NCT05540626
RWE Study Utilizing the Cala Trio Device in Patients With Essential Tremor
Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
276
Actual
Start
Apr 8, 2021
Primary completion
Mar 1, 2024
Study completion Mar 1, 2024
Sponsor
- Lead sponsor
- Cala Health, Inc.Not on our public-company list
- Sponsor type
- Industry
- Collaborators
- CVS Healthspire Life Sciences Solutions
- First posted
- Sep 14, 2022
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 22 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study objective is to evaluate hand tremor relief in the treated hand following stimulation with the Cala Trio Device in adults with essential tremor, and healthcare resource utilization and total healthcare costs over a 12-month period.
Conditions
- Essential Tremor
Interventions
Cala TrioDevice
transcutaneous afferent patterned stimulation (TAPS)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in tremor powerTime frame: 1 Month
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cala Health
San Mateo, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.